Masanobu Usui

ORCID: 0000-0003-2882-0994
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Pancreatic and Hepatic Oncology Research
  • Liver Disease and Transplantation
  • Organ Transplantation Techniques and Outcomes
  • Liver Disease Diagnosis and Treatment
  • Neuroendocrine Tumor Research Advances
  • Cholangiocarcinoma and Gallbladder Cancer Studies
  • Pancreatitis Pathology and Treatment
  • Renal Transplantation Outcomes and Treatments
  • Gallbladder and Bile Duct Disorders
  • Hepatocellular Carcinoma Treatment and Prognosis
  • Gastrointestinal Tumor Research and Treatment
  • Eicosanoids and Hypertension Pharmacology
  • Blood Coagulation and Thrombosis Mechanisms
  • Complement system in diseases
  • Gastric Cancer Management and Outcomes
  • Venous Thromboembolism Diagnosis and Management
  • Cancer Genomics and Diagnostics
  • Abdominal vascular conditions and treatments
  • Inflammatory Biomarkers in Disease Prognosis
  • Fatty Acid Research and Health
  • Hepatitis C virus research
  • Hepatitis B Virus Studies
  • Antifungal resistance and susceptibility
  • Nitric Oxide and Endothelin Effects
  • Multiple and Secondary Primary Cancers

Fujita Health University
2023-2025

Fujita Health University Hospital
2020-2023

Mie University
2011-2020

Eastern Hepatobiliary Surgery Hospital
2017

Second Military Medical University
2017

Mie University Hospital
2006-2016

Nippon Steel Yawata Memorial Hospital
2014

Mayo Clinic
2008

University Hospitals of Derby and Burton NHS Foundation Trust
2008

Samsung Medical Center
2008

Purpose: To retrospectively evaluate the long-term results of radiofrequency (RF) ablation combined with chemoembolization (combination therapy) as compared hepatectomy for treatment early-stage hepatocellular carcinoma (HCC). Materials and Methods: The study was approved by institutional review board, informed consent waived. Patients HCC were included if they underwent either combination therapy or met following inclusion criteria: no previous HCC, three fewer tumors a maximum diameter 3...

10.1148/radiol.2471070818 article EN Radiology 2008-02-28

Abstract Background Optimal treatment types and prognosis for patients with borderline resectable pancreatic cancer (BRPC) remain unclear because of the lack studies involving large series patients. Methods We retrospectively analyzed various prognostic factors 624 BRPC (pancreatic head/body) treated from June 2002 to May 2007, by distributing questionnaires member institutions Japanese Society Pancreatic Surgery in 2010. was defined according National Comprehensive Cancer Network (NCCN)...

10.1007/s00534-013-0595-1 article EN Journal of Hepato-Biliary-Pancreatic Sciences 2013-03-13

The neck clipping of cerebral aneurysms is a well-established treatment for subarachnoid hemorrhage (SAH) caused by aneurysmal rupture. However, it still unclear how great risk recurrence patients with successfully treated aneurysm carry over long-term period.Of 425 SAH surgically in Aizu Chuou Hospital from 1976 to 1994, 220 cases meeting the following criteria were studied: (1) all detected 3- or 4-vessel angiography clipped, (2) complete obliteration aneurysm(s) was confirmed...

10.1161/01.str.29.12.2511 article EN Stroke 1998-12-01

Background and Purpose —Recent progress in noninvasive imaging techniques has resulted increased detection of unruptured aneurysms. Although many neurosurgeons advocate surgical intervention for such aneurysms, the long-term results surgery aneurysms have not been carefully investigated. Methods —We analyzed 173 consecutive patients who had intracranial saccular aneurysm(s) detected by angiography that was performed reasons other than subarachnoid hemorrhage (SAH). Of those, 115 cases were...

10.1161/01.str.30.6.1181 article EN Stroke 1999-06-01

Despite the development of several therapeutic options, prognosis pancreatic cancer remains poor. One reason for this is difficulty diagnosing disease at an early stage. For example, carbohydrate antigen (CA) 19-9, which most widely used biomarker cancer, cannot be to detect stages. Some studies have attempted find novel biomarkers cancer. The aim present study was a diagnostic ductal adenocarcinoma (PDAC) in urine exosomes. Exosomes were isolated from and serum samples patients with PDAC...

10.3892/ol.2020.11357 article EN Oncology Letters 2020-01-29

We aimed to determine the relationship between intratumoral expression of human equilibrative nucleoside transporter (hENT1), main gemcitabine into cells, and outcome gemcitabine-based chemoradiotherapy (Gem-CRT) in patients with International Union Against Cancer (UICC) T3-T4 pancreatic adenocarcinoma.The expressions hENT1, thymidylate synthase (TS), dihydropyrimidine dehydrogenase were immunohistochemically analyzed using resected specimens from 55 (T3, 38 T4, 17) who had received...

10.1007/s00534-011-0440-3 article EN Journal of Hepato-Biliary-Pancreatic Sciences 2011-09-06

This study aimed to evaluate the efficacy of gemcitabine-based chemoradiotherapy followed by surgery (gem-CRTS) for pancreatic ductal adenocarcinoma (PDAC) borderline resectable (BR) and locally unresectable (UR) tumors.One hundred patients with PDAC who underwent gem-CRTS protocol were classified into 3 groups, namely, (R; 14), BR (44), UR (42). After chemoradiotherapy, reassessed curative-intent resection.At reassessment, distant metastases became apparent in 27% R patients, 12% 18%...

10.1097/mpa.0000000000000059 article EN cc-by-nc-nd Pancreas 2014-03-11

The aim of the present study was to evaluate perioperative risk factors for development nonalcoholic fatty liver disease (NAFLD) after pancreaticoduodenectomy (PD), paying special attention remnant pancreatic volume (RPV) and postoperative infection.We reviewed charts 110 patients who had been followed more than 6 months PD. These were classified into two groups according RPV measured by CT volumetry at one month: large-volume group (LVG) (10 ml or more, n = 75) small-volume (SVG) (less 10...

10.1002/jhbp.115 article EN Journal of Hepato-Biliary-Pancreatic Sciences 2014-05-14

Background: The aim of this study was to validate a new definition borderline resectable pancreatic ductal adenocarcinoma (PDAC) provided by the 2017 international consensus on basis three dimensions anatomical (A), biological (B), and conditional (C) factors, using data patients who had been registered for our institutional protocol chemoradiotherapy followed surgery (CRTS) localized with PDAC. Methods: Among 307 consecutive pathologically diagnosed PDAC were enrolled in CRTS from February...

10.3390/cancers10030065 article EN Cancers 2018-03-05

Although several therapeutic options are available for hepatocellular carcinoma (HCC), the outcome is still very poor. One reason complexity of signal transduction in pathogenesis HCC. The aim this study was to identify new HCC-related genes and investigate functions these progression Whole genomes 15 surgically resected HCC specimens were examined copy number alterations with comparative genomic hybridization. Gene expression compared between normal liver tissues. roles studied using...

10.3892/ijo.2014.2445 article EN cc-by-nc International Journal of Oncology 2014-05-19

Objective: The aim of the study was to identify prognostic factors before neoadjuvant chemoradiotherapy (NCRT) in patients with localized PDAC. Furthermore, post-surgical survival predictors LAPC. Summary background data: Surgical resection may occupy an important position multimodal therapy for LAPC; however, its indication and who obtains true benefits, is still uncovered. Materials Method: From 2005 2017, 319 PDAC underwent NCRT were reviewed. Only 159 diagnosed LAPC, these 72 surgical...

10.1097/sla.0000000000004148 article EN cc-by-nc-nd Annals of Surgery 2020-07-21

Opioid-induced constipation (OIC) is a common adverse drug event in patients undergoing chronic pain therapy. Naldemedine an oral, peripherally acting μ-opioid receptor antagonist that improves bowel movement without affecting opioid relief. In palliative wards, many experience malnutrition caused by cachexia and systemic inflammation because of cancer progression. We investigated whether the C-reactive protein-to-albumin ratio (CAR) affects continuation naldemedine therapy ward. included...

10.21873/invivo.13965 article EN In Vivo 2025-04-28

Objectives Although the prognostic benefit of neoadjuvant chemoradiotherapy (NCRT) against pancreatic cancer has been indicated by several reports, it is controversial whether histological response associated with prognosis. The objective was to explore relationship between and prognosis in T3 T4 adenocarcinoma. Methods We histologically examined resected specimens obtained from 58 patients (T3, n = 40; T4, 18) for whom we performed curative-intent resection after NCRT. Histological...

10.1097/mpa.0b013e3182236442 article EN Pancreas 2011-10-04

Abstract Background The prognosis of patients with perihilar cholangiocarcinoma have been unsatisfactory. We established new anatomical resectability classification for localized and performed neoadjuvant chemotherapy followed by curative-intent surgery based on its lymph node status to improve prognosis. This study aimed clarify the long-term outcomes validation our strategy. Methods Between September 2010 August 2018, 72 consecutive were classified into three groups: Resectable (R = 29),...

10.1186/s12885-020-06895-1 article EN cc-by BMC Cancer 2020-05-11

Purpose: To examine whether Functional Independence Measure (FIM) scores on admission can predict the future care levels of patients after acute stroke. Methods: In this multicenter retrospective cohort study, we enrolled post-acute stroke and assessed subtypes, self-care abilities using FIM scores, discharge destination. Patients' were according to Long-Term Care Insurance (LTCI) system (0–5: slight impairment bedridden), national insurance plan for in Japan, at discharge. We divided into...

10.3109/09638288.2014.918195 article EN Disability and Rehabilitation 2014-05-15

This study aimed to clarify whether pretreatment human equilibrative nucleoside transporter (hENT1) expressions in endoscopic ultrasonography-guided fine-needle aspiration biopsy (EUS-FNAB) specimens obtained from resectable, borderline and locally advanced unresectable pancreatic ductal adenocarcinoma (PDAC) are concordant with those the resected specimen after gemcitabine-based chemoradiotherapy (Gem-CRT) validate utility of hENT1 expression using EUS-FNAB samples as a prognostic marker.We...

10.1097/mpa.0000000000000597 article EN Pancreas 2016-01-19

For pancreatic ductal adenocarcinoma (PDAC) of the head and/or body invading splenic artery (SA), we developed a new surgical technique proximal subtotal pancreatectomy with and vein resection, so-called pancreaticoduodenectomy resection (PD-SAR). We retrospectively reviewed total 84 patients curative intent (PD) for PDAC body. These were classified into two groups: conventional PD (n=66) PD-SAR (n=18). Most treated by preoperative chemoradiotherapy (CRT). Postoperative MDCT clearly...

10.1155/2014/219038 article EN BioMed Research International 2014-01-01

Background: In many malignancies, including pancreatic ductal adenocarcinoma (PDAC), host-related inflammatory/immunonutritional markers, such as the prognostic nutritional index (PNI), modified Glasgow score (mGPS), and C-reactive protein (CRP)/albumin ratio are reported to be factors. However, influence of these factors before after chemoradiotherapy (CRT) has not been studied in PDAC patients. Methods: Of 261 consecutive patients who were scheduled for CRT with gemcitabine or S1 plus...

10.3390/cancers11040514 article EN Cancers 2019-04-10

Abstract Background Tumor budding (TB) is used as an indicator of poor prognosis in various cancers. However, studies on TB perihilar cholangiocarcinoma are still limited. We examined the significance resected with or without neoadjuvant therapy. Methods Seventy-eight patients who underwent surgical resection at our institution for from 2004 to 2017, (36 therapy), were enrolled this study. was defined isolated cancer cell clusters (< 5 cells) invasive front and number counted using a 20...

10.1186/s12885-020-6695-9 article EN cc-by BMC Cancer 2020-03-12
Coming Soon ...